Vaxxinity is developing the first multitope peptide-based vaccine for COVID-19 and has a commercial antibody test available under US FDA EUA. The vaccine candidate activates both an antibody response and a T-cell response to SARS-CoV-2 for robust protection.
Vaxxinity’s proven, innovative platform has the power to activate different arms of the immune system selectively, and to neutralize targets with high specificity
Vaxxinity will be a newly formed entity merging United Neuroscience and COVAXX, both spinouts of the United Biomedical Group
The body’s immune system is the best defense against disease. With its peptide-based platform, Vaxxinity “programs” the immune system for an effective response against a potentially broad set of indications, both chronic and infectious. Vaxxines can break immune tolerance to turn the body into an “antibody factory,” far more cost effective than developing and producing monoclonals.
Vaxxinity is focused on rapidly developing the first multitope peptide-based vaccine for COVID-19. Our approach is to utilize the clinically and commercially proven UBITh peptide vaccine platform to develop a high precision COVID-19 vaccine.